Biocon Q3 profit zooms twofold to Rs 217 crore
Biocon consolidated revenue from operations stood at Rs 1,540.8 crore for the quarter, against Rs 1,057.9 crore, it added.
New Delhi: Biotechnology major Biocon recently reported over a twofold jump in consolidated net profit to Rs 217.2 crore for the third quarter ended December 2018, mainly on account of the strong performance of its biologics business.
The company had posted a net profit of Rs Rs 91.9 crore for the corresponding period of the previous fiscal, Biocon said in a filing to the BSE.
Its consolidated revenue from operations stood at Rs 1,540.8 crore for the quarter, against Rs 1,057.9 crore, it added.
Biocon Limited is an Indian biopharmaceutical company based in Bangalore. The Company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe.
Also Read: Biocon net profit plunges 46 per cent in Q3
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd